July 5, 2018
Nativis Research Partner Presents at the International Symposium on Pediatric Neuro-Oncology Annual Meeting in Denver
Novel approach to treatment of diffuse midline glioma (DMG) using Nativis Voyager system
SEATTLE – JULY 05, 2018 – Nativis, Inc., clinical-stage life science therapeutic device company developing non-sterile, non-invasive and non-thermal treatments for cancers and other serious diseases, today announced a novel approach to treatment of pediatric brain cancer using its ultra-low radio frequency energy (ulRFE). A poster was presented at The International Symposium on Pediatric Neuro-Oncology (ISPNO) held at the Hyatt Regency Hotel in Denver from June 30 through July 3, 2018.
ISPNO is a biennial international meeting that welcomes oncologists, neurosurgeons, radiation oncologists, neurologists, nurses, basic and translational laboratory researchers, neuropathologists, neuroradiologists, endocrinologists, psychologists and social workers involved in the research for and diagnosis, treatment, rehabilitation and overall care for children with central nervous system (CNS) tumors across the world.
The poster was authored by Michael E. Salacz, M.D., Departments of Internal Medicine (Oncology) and Neurosurgery, University of Kansas, Kansas City; Donna Morgan Murray, Ph.D., Nativis; and Richard E. Kast, M.D., IIAIGC Study Center. The poster described an approach to treatment using a repurposed drug cocktail in combination with mitotic inhibition that can provide a meaningful therapeutic and minimally toxic benefit in DMG. This type of approach, using existing FDA-approved medications, would speed protocol development from the bench to the bedside. A compassionate-use study will begin enrolling pediatric patients, using the repurposed drug cocktail in combination with a newly developed Nativis Voyager pediatric system.
“The encouraging data from our clinical partners and other studies demonstrate that ulRFE can be used in various ways to knock down specific key pathways associated with cancer signaling,” said Chris E. Rivera, Chief Executive Officer of Nativis. “Our novel technology has the potential to transform the way we treat brain cancer, especially in children. With this encouraging data in hand, we will continue to develop the Nativis Voyager system for the treatment of glioblastoma in adults and will aim to expand to treatment of DMG, including diffuse intrinsic pontine glioma.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, Washington, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted ulRFE to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-sterile, non-invasive, non-thermal investigational device called the Nativis Voyager system. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of medical conditions as well as to veterinary medicine and non-medical applications. Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in oncology and pain treatment. Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.
Media Relations Contact:
Back to News